(MedPage Today) — The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the respective drugmakers.
The agency had…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116000
Author :
Publish date : 2025-06-10 19:00:00
Copyright for syndicated content belongs to the linked Source.
